Abstract:Focal cortical dysplasias are a common subtype of malformation of cortical development, which frequently presents with a spectrum of cognitive and behavioural abnormalities as well as pharmacoresistant epilepsy. Focal cortical dysplasia type II is typically caused by somatic mutations resulting in mammalian target of rapamycin (mTOR) hyperactivity, and is the commonest pathology found in children undergoing epilepsy surgery. However, surgical resection does not always result in seizure freedom, and is often precluded by proximity to eloquent brain regions. Gene therapy is a promising potential alternative treatment and may be appropriate in cases that represent an unacceptable surgical risk. Here, we evaluated a gene therapy based on overexpression of the Kv1.1 potassium channel in a mouse model of frontal lobe focal cortical dysplasia. An engineered potassium channel (EKC) transgene was placed under control of a human promoter that biases expression towards principal neurons (CAMK2A) and packaged in an adeno-associated viral vector (AAV9). We used an established focal cortical dysplasia model generated by in utero electroporation of frontal lobe neural progenitors with a constitutively active human Ras homolog enriched in brain (RHEB) plasmid, an activator of mTOR complex 1. We characterized the model by quantifying electrocorticographic and behavioural abnormalities, both in mice developing spontaneous generalized seizures and in mice only exhibiting interictal discharges. Injection of AAV9-CAMK2A-EKC in the dysplastic region resulted in a robust decrease (∼64%) in the frequency of seizures. Despite the robust anti-epileptic effect of the treatment, there was neither an improvement nor a worsening of performance in behavioural tests sensitive to frontal lobe function. AAV9-CAMK2A-EKC had no effect on interictal discharges or behaviour in mice without generalized seizures. AAV9-CAMK2A-EKC gene therapy is a promising therapy with translational potential to treat the epileptic phenotype of mTOR-related malformations of cortical development. Cognitive and behavioural co-morbidities may, however, resist an intervention aimed at reducing circuit excitability.

Combinatorial gene therapy for epilepsy: Gene sequence positioning and AAV serotype influence expression and inhibitory effect on seizures

Gene therapy for epilepsy targeting neuropeptide Y and its Y2 receptor to dentate gyrus granule cells

Global brain delivery of neuroligin 2 gene ameliorates seizures in a mouse model of epilepsy

Adeno-Associated Viral Vectors in the Treatment of Epilepsy

A novel AAV9-dual microRNA-vector targeting GRIK2 in the hippocampus as a treatment for mesial temporal lobe epilepsy

Drug-Inducible Gene Therapy Effectively Reduces Spontaneous Seizures in Kindled Rats but Creates Off-Target Side Effects in Inhibitory Neurons

Inhibition of epileptiform activity by neuropeptide Y in brain tissue from drug-resistant temporal lobe epilepsy patients

Revoking the Seize Order: Preventing Spontaneous Seizures With AAV in a CLN2 Mouse Model

GluK2 Is a Target for Gene Therapy in Drug-Resistant Temporal Lobe Epilepsy

Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection

Common AAV gene therapy vectors show indiscriminate transduction of living human brain cell types

Pharmaco-genetic Therapeutics Targeting Parvalbumin Neurons Attenuate Temporal Lobe Epilepsy.

Anti-seizure gene therapy for focal cortical dysplasia

Intraparenchymal delivery of adeno-associated virus vectors for the gene therapy of neurological diseases

Substantially improved gene transfer to interneurons with second-generation glutamate receptor-targeted DART-AAV vectors

Selective transgene expression in cerebellar Purkinje cells and granule cells using adeno-associated viruses together with specific promoters

AAV9-mediated targeting of natural antisense transcript as a novel treatment for Dravet Syndrome

AAV-based in vivo gene therapy for neurological disorders

Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy

Simple improvements in vector design afford substantial gains in AAV delivery of aggregation-slowing Aβ variants

Exogenous Nav1.1 activity in excitatory and inhibitory neurons reverts Dravet syndrome comorbidities when delivered post-symptom onset in mice with Dravet